|||
利用汤森路透科技集团的基本科学指标库(Essential Science Indicators)2004-2010间的高被引论文及其同被引聚类分析,通过同被引而密切关联的相关论文聚类形成若干个科学研究领域,由此绘制科学文献所反映的科学研究结构地图,讨论科学发展的基本格局。通过研究和揭示科学结构及其演化,为各领域研究提供一种思考问题、发现潜在交叉学科、“热点”领域。
/******************************************************************/
第一部分:RA 10 的基本信息
/******************************************************************/
RA ID: 10 | ||||||
RA的名称 | 雷帕霉素靶蛋白(mTOR)、磷酸肌醇3激酶(pi3k)信号通路与疾病发生的关系 | |||||
RA的关键词 | mammalian target; pik3ca gene; protects against age- and diet-induced obesity while enhancing insulin sensitivity; pathway activation through a pi3k-dependent feedback loop in human cancer; rictor-mtor complex integrity and regulates akt phosphorylation and substrate specificity; mapk pathway activation through a pi3k-dependent feedback loop in human; sin1/mip1 maintains rictor-mtor complex integrity and regulates akt phosphorylation and; s6k1 protects against age- and diet-induced obesity while enhancing insulin; maintains rictor-mtor complex integrity and regulates akt phosphorylation and substrate; ras/erk signaling promotes site-specific ribosomal protein s6 phosphorylation via rsk | |||||
包含RF数(Hot RF数) | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | ||
9(4) | 74 | 3792 | 8792 | 2006.7 | ||
该RA中包含RF的图谱 | ||||||
核糖体蛋白S6激酶磷酸化的调节作用 mTORC1与mTORC2、氨基酸对mTOR的调控机制、mTOR对akt/makp信号通路的调节 | ||||||
RA概述 | ||||||
雷帕霉素(Rapamycin)自20世纪70年代开发出来便经常作为免疫抑制剂用于器官移植,以减缓器官移植手术后的免疫排斥反应,特别是肾移植。雷帕霉素的涂层支架已为成千上万的冠心病患者解决了冠脉支架植入后的再狭窄问题,此外,新近发现雷帕霉素相关产品还是许多癌症治疗的重要靶向药物的选择。雷帕霉素靶蛋白(mTOR)作为细胞内激酶,是高分子量丝氨酸-苏氨酸激酶、磷酸肌醇3-激酶(PI3K)相关激酶(PIKK)的家族成员。近几年的研究发现mTOR传导通路的异常也可以诱发许多疾病。mTOR信号通路在神经疾病和抗衰老、炎症性疾病、纤维化疾病、肺动脉高压等诸多领域研究活跃,具有无限的市场应用前景。而对mTOR进行抑制便成为治疗与该通路密切相关的肿瘤包括肾癌、淋巴瘤、肺癌、肝癌、乳腺癌、神经内分泌癌和胃癌等的靶点所在。 |
/******************************************************************/
第二部分:RA 10 包含的9个RF的基本信息
/******************************************************************/
RF ID: 6247 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
25 | 1434 | 3625 | 2007.5 | Yes |
RF的关键词 | mtor-mediated translational control molecular mechanisms; mtor complex 2 (mtorc2) controls hydrophobic motif phosphorylation; intact mtor signaling complex 2; pras40 regulates mtorc1 kinase activity; mammalian tor complex 2 controls | |||
RF ID: 6714 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
20 | 987 | 2012 | 2007.3 | No |
RF的关键词 | mtor/phosphatidylinositol 3-kinase inhibitor nvp-bez235 lapatinib resistance reversal; vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug; pi 3-kinase p110 beta | |||
RF ID: 8254 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
11 | 900 | 2120 | 2005.5 | No |
RF的关键词 | oncogenic pi3k alpha mutations; phosphatidylinositol 3-kinase mutations identified; human breast cancers; human p110 alpha/p85 alpha complex elucidates; pik3ca mutations correlate | |||
RF ID: 11354 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
5 | 387 | 817 | 2005.0 | No |
RF的关键词 | amino acid mtor/raptor signaling class-3 phosphatidylinosital 30h-kinase mediation; nutrient-regulated lipid kinase required; mammalian target; amino acid sufficiency; p70 s6 kinase | |||
RF ID: 13303 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
3 | 505 | 849 | 2004.0 | No |
RF的关键词 | tsc/rheb/mtor/s6k cassette inappropriate activation induces irs1/2 depletion-insulin resistance-cell survival deficiencies; enhancing insulin sensitivity; insulin resistance; tsc1-2 tumor suppressor controls insulin-p13k signaling | |||
RF ID: 14863 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
3 | 315 | 405 | 2005.6 | No |
RF的关键词 | ras/erk signaling; site-specific ribosomal protein s6 phosphorylation; mitogen-activated protein kinase-dependent s6 kinase pathway; protein synthesis; rapamycin-sensitive 5 ''-terminal oligopyrimidine mrna translation | |||
RF ID: 9782 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
3 | 395 | 574 | 2006.0 | Yes |
RF的关键词 | mtor inhibition induces upstream receptor tyrosine kinase signaling; rapamycin induces feedback activation; akt signaling; rapamycin inhibition; activates akt | |||
RF ID: 7986 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
2 | 72 | 120 | 2008.0 | Yes |
RF的关键词 | erk mapk signaling; hormone-refractory prostate cancer; mapk pathway activation; human cancer; pi3k-dependent feedback loop; preclinical mouse model | |||
RF ID: 12550 | ||||
核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
2 | 70 | 108 | 2008.0 | Yes |
RF的关键词 | oncogenic cellular transformation; class ipi3k; pi3k/akt pathway; cancer; drug discovery |
/******************************************************************/
第三部分:9个RF的核心论文详细列表
/******************************************************************/
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
6247 | 25 | 1434 | 3625 | 2007.5 | Yes |
RF的关键词 | mtor-mediated translational control molecular mechanisms; mtor complex 2 (mtorc2) controls hydrophobic motif phosphorylation; intact mtor signaling complex 2; pras40 regulates mtorc1 kinase activity; mammalian tor complex 2 controls |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
phosphorylation and regulation of akt/pkb by the rictor-mtor complex | 1007 | 2005 | SCIENCE | SARBASSOV DD | MIT, USA |
rictor, a novel binding partner of mtor, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | 457 | 2004 | CURR BIOL | SARBASSOV DD | MIT, USA |
prolonged rapamycin treatment inhibits mtorc2 assembly and akt/pkb | 348 | 2006 | MOL CELL | SARBASSOV DD | Whitehead Inst Biomed Res, USA |
mammalian tor complex 2 controls the actin cytoskeleton and is rapamycin insensitive | 315 | 2004 | NAT CELL BIOL | JACINTO E | Univ Basel, Switzerland |
sin1/mip1 maintains rictor-mtor complex integrity and regulates akt phosphorylation and substrate specificity | 190 | 2006 | CELL | JACINTO E | Univ Texas, USA |
mtor center dot rictor is the ser(473) kinase for akt/protein kinase b in 3t3-l1 adipocytes | 174 | 2005 | J BIOL CHEM | HRESKO RC | Washington Univ, USA |
ablation in mice of the mtorc components raptor, rictor, or mlst8 reveals that mtorc2 is required for signaling to akt-foxo and pkc alpha but not s6k1 | 164 | 2006 | DEV CELL | GUERTIN DA | MIT, USA |
pras40 is an insulin-regulated inhibitor of the mtorc1 protein kinase | 141 | 2007 | MOL CELL | SANCAK Y | MIT, USA |
ampk phosphorylation of raptor mediates a metabolic checkpoint | 130 | 2008 | MOL CELL | GWINN DM | Salk Inst Biol Studies, USA |
insulin signalling to mtor mediated by the akt/pkb substrate pras40 | 118 | 2007 | NAT CELL BIOL | VANDER HAAR E | Univ Minnesota, USA |
the rag gtpases bind raptor and mediate amino acid signaling to mtorc1 | 114 | 2008 | SCIENCE | SANCAK Y | MIT, USA |
msin1 is necessary for akt/pkb phosphorylation, and its isoforms define three distinct mtorc2s | 93 | 2006 | CURR BIOL | FRIAS MA | MIT, USA |
regulation of torc1 by rag gtpases in nutrient response | 66 | 2008 | NAT CELL BIOL | KIM E | Univ Calif San Diego, USA |
pras40 regulates mtorc1 kinase activity by functioning as a direct inhibitor of substrate binding | 63 | 2007 | J BIOL CHEM | WANG LF | Univ Virginia Hlth Syst, USA |
active-site inhibitors of mtor target rapamycin-resistant outputs of mtorc1 and mtorc2 | 51 | 2009 | PLOS BIOL | FELDMAN ME | Univ Calif San Francisco, USA |
mtor complex 2 (mtorc2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (sgk1) | 43 | 2008 | BIOCHEM J | GARCIA-MARTINEZ JM | Univ Dundee, Scotland |
molecular mechanisms of mtor-mediated translational control | 41 | 2009 | NAT REV MOL CELL BIOL | MA XJM | Genentech Inc, USA |
mtor complex 2 is required for the development of prostate cancer induced by pten loss in mice | 24 | 2009 | CANCER CELL | GUERTIN DA | Whitehead Inst Biomed Res, USA |
biochemical, cellular, and in vivo activity of novel atp-competitive and selective inhibitors of the mammalian target of rapamycin | 21 | 2009 | CANCER RES | YU K | Wyeth Res, USA |
ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mtor) | 20 | 2009 | BIOCHEM J | GARCIA-MARTINEZ JM | Univ Dundee, Scotland |
torc-specific phosphorylation of mammalian target of rapamycin (mtor): phospho-ser(2481) is a marker for intact mtor signaling complex 2 | 15 | 2009 | CANCER RES | COPP J | Salk Inst Biol Studies, USA |
rictor/torc2 regulates caenorhabditis elegans fat storage, body size, and development through sgk-1 | 15 | 2009 | PLOS BIOL | JONES KT | Univ Calif San Francisco, USA |
the pharmacology of mtor inhibition | 7 | 2009 | SCI SIGNAL | GUERTIN DA | Nine Cambridge Ctr, USA |
differential requirement of mtor in postmitotic tissues and tumorigenesis | 4 | 2009 | SCI SIGNAL | NARDELLA C | Harvard Univ, USA |
characterization of the intrinsic and tsc2-gap-regulated gtpase activity of rheb by real-time nmr | 4 | 2009 | SCI SIGNAL | MARSHALL CB | Univ Hlth Network, Canada |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
6714 | 20 | 987 | 2012 | 2007.3 | No |
RF的关键词 | mtor/phosphatidylinositol 3-kinase inhibitor nvp-bez235 lapatinib resistance reversal; vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug; pi 3-kinase p110 beta |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
pten activation contributes to tumor inhibition by trastuzumab, and loss of pten predicts trastuzumab resistance in patients | 394 | 2004 | CANCER CELL | NAGATA Y | Univ Texas, USA |
a pharmacological map of the pi3-k family defines a role for p110 alpha in insulin signaling | 253 | 2006 | CELL | KNIGHT ZA | Univ Calif San Francisco, USA |
a dual pi3 kinase/mtor inhibitor reveals emergent efficacy in glioma | 190 | 2006 | CANCER CELL | FAN QW | Univ Calif San Francisco, USA |
a functional genetic approach identifies the pi3k pathway as a major determinant of trastuzumab resistance in breast cancer | 155 | 2007 | CANCER CELL | BERNS K | Netherlands Canc Inst, Netherlands |
insulin-like growth factor-i receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | 144 | 2005 | CANCER RES | NAHTA R | Univ Texas, USA |
pi 3-kinase p110 beta: a new target for antithrombotic therapy | 137 | 2005 | NATURE MED | JACKSON SP | Monash Univ, Australia |
critical role for the p110 alpha phosphoinositide-3-oh kinase in growth and metabolic regulation | 101 | 2006 | NATURE | FOUKAS LC | Ludwig Inst Canc Res, England |
identification and characterization of nvp-bez235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | 99 | 2008 | MOL CANCER THER | MAIRA SM | Novartis Pharma AG, Switzerland |
pharmacologic characterization of a potent inhibitor of class i phosphatidylinositide 3-kinases | 86 | 2007 | CANCER RES | RAYNAUD FI | Inst Canc Res, England |
effective use of pi3k and mek inhibitors to treat mutant kras g12d and pik3ca h1047r murine lung cancers | 70 | 2008 | NATURE MED | ENGELMAN JA | Beth Israel Hosp, USA |
essential roles of pi(3)k-p110 beta in cell growth, metabolism and tumorigenesis | 61 | 2008 | NATURE | JIA SD | Dana Farber Canc Inst, USA |
a vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, sf1126, with antitumor and antiangiogenic activity | 50 | 2008 | CANCER RES | GARLICH JR | Aflac Canc Ctr & Blood Disorders Serv, USA |
nvp-bez235, a dual pi3k/mtor inhibitor, prevents pi3k signaling and inhibits the growth of cancer cells with activating pi3k mutations | 50 | 2008 | CANCER RES | SERRA V | Vall Hebron Univ Hosp, Spain |
the identification of 2-(1h-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (gdc-0941) as a potent, selective, orally bioavailable inhibitor of class ipi3 kinase for the treatment of cancer | 50 | 2008 | J MED CHEM | FOLKES AJ | Piramed Pharma, England |
angiogenesis selectively requires the p110 alpha isoform of pi3k to control endothelial cell migration | 49 | 2008 | NATURE | GRAUPERA M | Canc Res UK London Res Inst, England |
the p110 beta isoform of phosphoinositide 3-kinase signals downstream of g protein-coupled receptors and is functionally redundant with p110 gamma | 45 | 2008 | PROC NAT ACAD SCI USA | GUILLERMET-GUIBERT J | Queen Mary Univ London, England |
phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mtor/phosphatidylinositol 3-kinase inhibitor nvp-bez235 | 35 | 2008 | CANCER RES | EICHHORN PJA | Vall Hebron Univ Hosp, Spain |
mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor px-866 whereas oncogenic ras is a dominant predictor for resistance | 16 | 2009 | CANCER RES | IHLE NT | MD Anderson Canc Ctr, USA |
akt-independent signaling downstream of oncogenic pik3ca mutations in human cancer | 14 | 2009 | CANCER CELL | VASUDEVAN KM | Harvard Univ, USA |
breast tumor cells with pi3k mutation or her2 amplification are selectively addicted to akt signaling | 13 | 2008 | PLOS ONE | SHE QB | Mem Sloan Kettering Canc Ctr, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
8254 | 11 | 900 | 2120 | 2005.5 | No |
RF的关键词 | oncogenic pi3k alpha mutations; phosphatidylinositol 3-kinase mutations identified; human breast cancers; human p110 alpha/p85 alpha complex elucidates; pik3ca mutations correlate |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
high frequency of mutations of the pik3ca gene in human cancers | 687 | 2004 | SCIENCE | SAMUELS Y | Johns Hopkins Univ, USA |
mutation of the pik3ca gene in ovarian and breast cancer | 245 | 2004 | CANCER RES | CAMPBELL IG | Peter MacCallum Canc Ctr, Australia |
phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic | 225 | 2005 | PROC NAT ACAD SCI USA | KANG SY | Scripps Res Inst, USA |
mutant pik3ca promotes cell growth and invasion of human cancer cells | 208 | 2005 | CANCER CELL | SAMUELS Y | Johns Hopkins Univ, USA |
pik3ca mutations correlate with hormone receptors, node metastasis, and erbb2, and are mutually exclusive with pten loss in human breast carcinoma | 190 | 2005 | CANCER RES | SAAL LH | Columbia Univ Coll Phys & Surg, USA |
the pik3ca gene is mutated with high frequency in human breast cancers | 161 | 2004 | CANCER BIOL THER | BACHMAN KE | Johns Hopkins Univ, USA |
pik3ca gene is frequently mutated in breast carcinomas and hepatocellular carcinomas | 146 | 2005 | ONCOGENE | LEE JW | Catholic Univ Korea, South Korea |
cancer-specific mutations in pik3ca are oncogenic in vivo | 95 | 2006 | PROC NAT ACAD SCI USA | BADER AG | Scripps Res Inst, USA |
the structure of a human p110 alpha/p85 alpha complex elucidates the effects of oncogenic pi3k alpha mutations | 68 | 2007 | SCIENCE | HUANG CH | Johns Hopkins Kimmel Canc Ctr, USA |
mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit | 61 | 2007 | SCIENCE | MILED N | MRC, England |
helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms | 34 | 2008 | PROC NAT ACAD SCI USA | ZHAO L | Scripps Res Inst, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
11354 | 5 | 387 | 817 | 2005.0 | No |
RF的关键词 | amino acid mtor/raptor signaling class-3 phosphatidylinosital 30h-kinase mediation; nutrient-regulated lipid kinase required; mammalian target; amino acid sufficiency; p70 s6 kinase |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
amino acids mediate mtor/raptor signaling through activation of class 3 phosphatidylinositol 30h-kinase | 217 | 2005 | PROC NAT ACAD SCI USA | NOBUKUNI T | Univ Utrecht, Netherlands |
rheb binds and regulates the mtor kinase | 198 | 2005 | CURR BIOL | LONG X | Massachusetts Gen Hosp, USA |
hvps34 is a nutrient-regulated lipid kinase required for activation of p70 s6 kinase | 177 | 2005 | J BIOL CHEM | BYFIELD MP | Albert Einstein Coll Med, USA |
the tuberous sclerosis protein tsc2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses | 115 | 2005 | J BIOL CHEM | SMITH EM | Univ British Columbia, Canada |
rheb binding to mammalian target of rapamycin (mtor) is regulated by amino acid sufficiency | 110 | 2005 | J BIOL CHEM | LONG XM | Harvard Univ, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
13303 | 3 | 505 | 849 | 2004.0 | No |
RF的关键词 | tsc/rheb/mtor/s6k cassette inappropriate activation induces irs1/2 depletion-insulin resistance-cell survival deficiencies; enhancing insulin sensitivity; insulin resistance; tsc1-2 tumor suppressor controls insulin-p13k signaling |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
absence of s6k1 protects against age- and diet-induced obesity while enhancing insulin sensitivity | 362 | 2004 | NATURE | UM SH | Friedrich Miescher Inst Biomed Res, Switzerland |
the tsc1-2 tumor suppressor controls insulin-p13k signaling via regulation of irs proteins | 278 | 2004 | J CELL BIOL | HARRINGTON LS | Inst Canc Res, England |
inappropriate activation of the tsc/rheb/mtor/s6k cassette induces irs1/2 depletion, insulin resistance, and cell survival deficiencies | 209 | 2004 | CURR BIOL | SHAH OJ | Salk Inst Biol Studies, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
14863 | 3 | 315 | 405 | 2005.6 | No |
RF的关键词 | ras/erk signaling; site-specific ribosomal protein s6 phosphorylation; mitogen-activated protein kinase-dependent s6 kinase pathway; protein synthesis; rapamycin-sensitive 5 ''-terminal oligopyrimidine mrna translation |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
s6k1(-/-)/s6k2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5 '-terminal oligopyrimidine mrna translation and reveal a mitogen-activated protein kinase-dependent s6 kinase pathway | 226 | 2004 | MOL CELL BIOL | PENDE M | INSERM 584, France |
ribosomal protein s6 phosphorylation: from protein synthesis to cell size | 118 | 2006 | TRENDS BIOCHEM SCI | RUVINSKY I | Hebrew Univ Jerusalem, Israel |
ras/erk signaling promotes site-specific ribosomal protein s6 phosphorylation via rsk and stimulates cap-dependent translation | 61 | 2007 | J BIOL CHEM | ROUX PP | Univ Montreal, Canada |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
9782 | 3 | 395 | 574 | 2006.0 | Yes |
RF的关键词 | mtor inhibition induces upstream receptor tyrosine kinase signaling; rapamycin induces feedback activation; akt signaling; rapamycin inhibition; activates akt |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
mtor inhibition induces upstream receptor tyrosine kinase signaling and activates akt | 318 | 2006 | CANCER RES | O'REILLY KE | Mem Sloan Kettering Canc Ctr, USA |
activation of akt and eif4e survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition | 162 | 2005 | CANCER RES | SUN SY | Emory Univ, USA |
rapamycin induces feedback activation of akt signaling through an igf-1r-dependent mechanism | 94 | 2007 | ONCOGENE | WAN X | NCI, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
7986 | 2 | 72 | 120 | 2008.0 | Yes |
RF的关键词 | erk mapk signaling; hormone-refractory prostate cancer; mapk pathway activation; human cancer; pi3k-dependent feedback loop; preclinical mouse model |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
inhibition of mtorc1 leads to mapk pathway activation through a pi3k-dependent feedback loop in human cancer | 77 | 2008 | J CLIN INVEST | CARRACEDO A | 77 Ave Louis Pasteur, USA |
targeting akt/mtor and erk mapk signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model | 43 | 2008 | J CLIN INVEST | KINKADE CW | Columbia Univ, USA |
RF ID | 核心论文数 | 被引用篇数 | 总被引次数 | 平均出版年 | 是否为热点 |
12550 | 2 | 70 | 108 | 2008.0 | Yes |
RF的关键词 | oncogenic cellular transformation; class ipi3k; pi3k/akt pathway; cancer; drug discovery |
论文题目 | 被引 | 年份 | 刊名 | 第一作者 | 第一机构、国家 |
drug discovery approaches targeting the pi3k/akt pathway in cancer | 65 | 2008 | ONCOGENE | GARCIA-ECHEVERRIA C | Novartis Inst Biomed Res, Switzerland |
class ipi3k in oncogenic cellular transformation | 43 | 2008 | ONCOGENE | ZHAO L | Scripps Res Inst, USA |
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-4-24 09:36
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社